The global single-use bioprocessing market was valued at USD 27.94 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 16.24% from 2024 to 2030. The adoption of single-use bioprocessing technology is driven by the growing demand for biopharmaceuticals over the past few years, along with an increase in investments for the development of biologics, such as monoclonal antibodies, vaccines, recombinant proteins, and others. Furthermore, benefits pertaining to the use of single-use technology, such as significant reduction in costs and time required for operations & facility construction have supported the implementation of single-use systems in the bioprocessing sector.The COVID-19 pandemic has generated new growth opportunities for key stakeholders in the industry. Key biopharmaceutical players can leverage the opportunity by expanding their COVID-19-related product offerings by scaling up their production facilities with the implementation of single-use bioprocessing equipment. A significant number of biopharmaceutical companies are actively involved in the development & production of COVID-19 vaccines. These programs are majorly based on single-use technologies as these systems are flexible, cost-effective, and reduce the risk of cross-contamination.
Get a preview of the latest developments in the Global Single-use Bioprocessing Market! Download your FREE sample PDF today and explore key data and trends
Such an ongoing and continuous increase in the adoption of these bioprocessing systems due to the COVID-19 pandemic is anticipated to drive industry growth. The commercial success of biopharmaceuticals has led single-use manufacturers to expand their production facilities globally. Capacity expansion projects have been a part of many manufacturers’ multi-year plans, to leverage a global reach and a broader customer base. For instance, in December 2020, Merck KGaA invested over USD 42 million to broaden its existing manufacturing facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, U.S.
This expansion was aimed at enhancing the company’s single-use assembly operations along with other product portfolios. Furthermore, with the rising focus on the development of regenerative medicine, such as cell and gene therapies, increased success of clinical trials, and enhanced rate of regulatory approvals, demand for commercialization of these products is expected to grow in the near future. In addition, owing to the increasing outsourcing activities in biopharmaceutical manufacturing, CMOs are adopting single-use systems for maintaining highly dynamic and frequently changing product portfolios.
Key Single-use Bioprocessing Companies:
The following are the leading companies in the single-use bioprocessing market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps & products of these single-use bioprocessing companies are analyzed to map the supply network.
Sartorius AG
Danaher
Thermo Fisher Scientific, Inc.
Merck KGaA
Avantor, Inc.
Eppendorf SE
Corning Incorporated
Lonza
PBS Biotech, Inc.
Meissner Filtration Products, Inc.
Gather more insights about the market drivers, restrains and growth of the Single-use Bioprocessing Market